Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q2 CY2025 results beating Wall Street’s revenue expectations, ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

The RMR Group secured a $1 billion refinancing for Vertex Pharmaceuticals' Boston Seaport headquarters, a five-year, interest ...

Vertex Pharmaceuticals Incorporated has been a hot topic lately, but it's crucial to dig into the details before investing.

The biotechnology industry is split between two very different types of companies. On one side are the large, blue-chip leaders like Amgen Inc. (ticker: AMGN), Gilead Sciences Inc.

Tweedy Browne’s Q2 2025 portfolio reveals disciplined value investing with key holdings in CNH, Berkshire Hathaway, and ...

Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

The latest update is out from Royalty Pharma ( (RPRX) ).

Commuters who work in the Raymond Flynn Marine Park just got a new option to add some more fluidity to their commute.

On Wednesday, 2230 stocks advanced, 1864 declined and 162 remained unchanged on Bombay Stock Exchange with advance decline ...